Targeted Therapies on Cancer and Inflammation Laboratory, Centro de Investigación Príncipe Felipe, Valencia, Spain.
FEBS J. 2022 Oct;289(20):6209-6234. doi: 10.1111/febs.16136. Epub 2021 Aug 2.
Myeloid cell leukemia-1 (MCL1), an antiapoptotic member of the BCL2 family characterized by a short half-life, functions as a rapid sensor that regulates cell death and other relevant processes that include cell cycle progression and mitochondrial homeostasis. In cancer, MCL1 overexpression contributes to cell survival and resistance to diverse chemotherapeutic agents; for this reason, several MCL1 inhibitors are currently under preclinical and clinical development for cancer treatment. However, the nonapoptotic functions of MCL1 may influence their therapeutic potential. Overall, the complexity of MCL1 regulation and function represent challenges to the clinical application of MCL1 inhibitors. We now summarize the current knowledge regarding MCL1 structure, regulation, and function that could impact the clinical success of MCL1 inhibitors.
髓样细胞白血病-1(MCL1)是 BCL2 家族中的一种抗凋亡成员,其半衰期较短,作为一种快速传感器发挥作用,调节细胞死亡和其他相关过程,包括细胞周期进程和线粒体动态平衡。在癌症中,MCL1 的过表达有助于细胞存活和对多种化疗药物的耐药性;因此,目前有几种 MCL1 抑制剂正在进行临床前和临床开发,用于癌症治疗。然而,MCL1 的非凋亡功能可能会影响它们的治疗潜力。总的来说,MCL1 调节和功能的复杂性给 MCL1 抑制剂的临床应用带来了挑战。我们现在总结了有关 MCL1 结构、调节和功能的最新知识,这些知识可能会影响 MCL1 抑制剂的临床成功。